Inhibition of the DNA damage checkpoint kinase WEE1 potentiates genotoxic chemotherapies by abrogating cell cycle arrest and proper DNA repair. However, WEE1 is also essential for unperturbed cell division in the absence of extrinsic insult. Here we investigate the anticancer potential of a WEE1 inhibitor, independent of chemotherapy, and explore a possible cellular context underlying sensitivity to WEE1 inhibition. We 
ABSTRACT
Inhibition of the DNA damage checkpoint kinase WEE1 potentiates genotoxic chemotherapies by abrogating cell cycle arrest and proper DNA repair. However, WEE1 is also essential for unperturbed cell division in the absence of extrinsic insult. Here we investigate the anticancer potential of a WEE1 inhibitor, independent of chemotherapy, and explore a possible cellular context underlying sensitivity to WEE1 inhibition. We demonstrate that MK-1775, a potent and selective ATP-competitive inhibitor of WEE1, is cytotoxic across a broad panel of tumor cell lines and induces DNA double strand breaks.
MK-1775-induced DNA damage occurs without added chemotherapy or radiation in S-phase cells and relies on active DNA replication. At tolerated doses, MK-1775 treatment leads to xenograft tumor growth inhibition or regression. To begin addressing potential response markers for MK-1775 monotherapy we focused on PKMYT1, a kinase functionally related to WEE1. Knockdown of PKMYT1 lowers the EC 50 of MK-1775 by 5-fold but has no effect on the cell-based response to other cytotoxic drugs. Additionally, knockdown of PKMYT1 increases markers of DNA damage, γH2AX and pCHK1 S345 , induced by MK-1775. In a posthoc analysis of 305 cell lines treated with MK-1775, we found expression of PKMYT1 was below average in 73% of the 33 most sensitive cell lines. Our findings provide rationale for WEE1 inhibition as a potent anticancer therapy independent of a genotoxic partner and suggest that low PKMYT1 expression could serve as an enrichment biomarker for MK-1775 sensitivity.
INTRODUCTION
Many commonly used anticancer drugs target DNA in dividing cells and ultimately cause DNA damage. This, in turn, triggers activation of cell cycle checkpoints which arrest progression of the cell cycle (at the G1, S, or G2/M phases) to allow the DNA to be repaired before the cell undergoes DNA replication and/or division. From a therapeutic standpoint, inhibition of checkpoint kinases that mediate cell cycle arrest could force tumor cells to continue cell division before chemically-induced DNA damage is repaired, eventually causing apoptosis or mitotic catastrophe (1) . Cell line studies support this hypothesis and show chemosensitization and radiosensitization by pharmacologic or genetic disruption of checkpoint kinase activity including CHK1, WEE1, ATR, ATM, and MK2. Inhibitors of these kinases are at various stages of preclinical and clinical development.
The checkpoint kinase WEE1 catalyzes an inhibitory phosphorylation of both CDK1 (CDC2) and CDK2 on tyrosine 15 (2;3). WEE1-dependent inhibition of CDK1 and CDK2 arrests the cell cycle in response to extrinsically induced DNA damage (4) . WEE1 activity is also essential for the unperturbed cell cycle (5;6). Cell synchronization studies in normal human fibroblasts revealed that similar amounts of WEE1 protein were detected in both S and G2/M phases, but that its greatest activity was in S phase of the cell cycle (3).
Furthermore, conditional knockout of WEE1 in mouse embryonic fibroblasts results in genomic instability, malfunctioning checkpoints, and premature mitosis (6) . This phenotype was explained in part by recent findings that demonstrate a critical role for WEE1 in DNA synthesis. Knockdown of WEE1 led to DNA double strand breaks specifically in S-phase cells undergoing DNA replication (7;8) . Data support a model of WEE1-dependent genomic stability in which WEE1 knockdown or inhibition leads to aberrantly high activity of CDK 1 and/or 2, resulting in inappropriately timed firing of excessive DNA replication origins. This in turn quickly depletes nucleotide pools and leads to stalled replication forks which, in the absence of WEE1 activity, are substrates for the DNA exonuclease SLX4-MUS81 and resolve into DNA double strand breaks (9) . Deregulated WEE1 expression and activity have been associated with several types of cancer. WEE1 is often overexpressed in glioblastomas where elevated levels of WEE1 mRNA are linked to poor prognosis (10) . High expression of WEE1 was found in malignant melanoma and correlated with poor disease-free survival in this population (11) . Aberrant WEE1 expression has been implicated in additional tumor types such as hepatocellular carcinoma (12) , breast cancer (13), colon carcinoma (14) , lung carcinoma (15) , and head and neck squamous cell carcinoma (16) . Advanced tumors with an increased level of genomic instability may require functional checkpoints to allow the repair of DNA perturbations that accompany genomic instability. Therefore, WEE1 might be an attractive target in advanced tumors where its inhibition may lead to irreparable DNA damage (reviewed in (17) ).
MK-1775 is a potent and selective ATP-competitive small molecule inhibitor of WEE1 (18) and is currently under clinical development as a chemosensitizer in combination with chemotherapeutics (19;20) . Due to the DNA damaging effects resulting from the loss of WEE1 activity, we hypothesized that targeted pharmacological inhibition of WEE1 in the absence of chemotherapy could be a viable anticancer strategy. We show that treatment with MK-1775 gives rise to DNA damage in S phase cells even in the absence of standard chemotherapeutic DNA damaging agents and that premature mitosis 5 is not required for its ability to inhibit cancer cell proliferation. At tolerated doses, MK-1775 leads to tumor growth inhibition (TGI) in multiple xenograft models. Like WEE1, PKMYT1 also phosphorylates and inhibits CDK1 and CDK2 so we questioned whether this kinase affected cell-based responses to MK-1775 treatment. Our data suggest that low PKMYT1 expression could be a determinant of MK-1775 sensitivity. The results presented here support the use of the WEE1 inhibitor MK-1775 as a DNA damaging anticancer therapy and suggest reduced PKMYT1 expression as a possible feature of the most responsive tumors to this agent. 
MATERIALS AND METHODS

Cell
Flow Cytometry and Cell Synchronization
Cells analyzed by flow cytometry were fixed overnight in ice-cold 70% ethanol and propidium iodide (PI)/RNase solution (BD Biosciences 550825) was used to determine total DNA content. To detect DNA double strand breaks, cells were stained with a FITC-conjugated anti-γH2AX (S139) antibody (Millipore kit 17-344). To define the mitotic population, cells were stained with an anti-pHH3-Alexa 647 antibody directed against phospho-serine 28 (BD Biosciences 558217).
For synchronization studies, cells were incubated in serum-free medium for 36 hours, followed by replenishment with 20% FBS. One hour prior to each harvest, cells were pulsed with 10 μM bromodeoxyuridine (BrdU). Cells were fixed and stained for BrdU and DNA content with an anti-BrdU FITC-conjugated antibody and with a 7-aminoactinomycin-D (7-AAD) dye, respectively, according to the instructions in the BD Pharmingen™ FITC BrdU Flow Kit (BD Biosciences 559619, 557891). All cytometry data were collected on the BD LSR II flow cytometer using Diva software, and results were analyzed in FlowJo version 7.5.
In Vivo Studies
CD-1 Nu/Nu female mice aged 5-6 weeks were obtained from Charles River 
RESULTS
Pharmacologic inhibition of WEE1 blocks proliferation in diverse tumor cell lines.
A wide array of responses was observed when 522 cancer lines representing 16 different tumor types were screened with a selective inhibitor of WEE1, MK-1775 ( figure   1A ; supplemental figure S1). Anti-proliferative EC 50 values ranged from < 0.1 µM in 2% Chromosomal breaks during DNA synthesis would be expected to activate the DNA replication checkpoint and slow progression through S phase. To address this we analyzed the effects of MK-1775 treatment on cell populations synchronized by serum depletion. We avoided cell synchronization approaches targeting DNA synthesis (e.g. double-thymidine block, aphidicolin, hydroxyurea, actinomycin D, etc.) because these methods are disruptive to DNA replication (causing stalled forks) and may confound analyses by inadvertently sensitizing cells to MK-1775 treatment. Instead, we opted to induce G0 synchronization through serum withdrawal. We selected the ES-2 line for these studies because they were amenable to synchronization by serum depletion.
WEE1 inhibition by MK-1775 causes DNA damage in S phase
Complete serum withdrawal for 36 hours in ES-2 cells did not reduce viability but shifted the G0/G1 fraction to 75% -80% (data not shown). Addition of 20% FBS caused vehicle- 
DNA damage underlies MK-1775-induced cytotoxicity
WEE1 is required for the temporal activation of both CDK2 and CDK1 in S and G2 phases of the cell cycle, respectively. Inhibition of WEE1, therefore, is expected to lead to both S phase defects (DNA double strand breaks during DNA replication) and G2-M defects (premature mitosis). To question whether either or both of these events is necessary or sufficient for MK-1775-driven cytotoxicity, we examined γH2AX and phosphorylated histone H3 (pHH3), a marker of mitosis, in three MK-1775 sensitive cell 
PKMYT1 expression can affect sensitivity to MK-1775 treatment
The majority of cancer cell lines that we treated with MK-1775 show at least some degree of sensitivity to MK-1775 treatment (supplemental figure S1) . However, not all cell lines are equally susceptible to WEE1 inhibition and anti-proliferative EC 50 s vary by as much as 10-fold (supplemental figure S1). One potential determinant of sensitivity to WEE1 inhibition is activity of a functionally related CDK-inhibitory kinase, PKMYT1. Since PKMYT1 knockdown leads to increased sensitivity to MK-1775, we reasoned that low PKMYT1 expression might be common among MK-1775-responsive cell lines. To address this, we used the Broad-Novartis Cancer Cell Line Encyclopedia (CCLE), a publicly available cell line database (27), to find PKMYT1 mRNA expression levels in the 522 cell lines that we had treated with MK-1775 (supplemental figure S1 ). proliferation-based sensitivities to MK-1775. Recent findings underscore a critical role for WEE1 in regulating appropriate initiation and progression of DNA replication forks, and thereby maintaining genomic integrity by preventing DNA double strand breaks during DNA replication (7-9;35). Kreahling et al. did not examine markers of DNA damage following MK-1775 treatment so the relative contribution of premature mitosis versus DNA damage cannot be appreciated. We also found that some cell lines display a large increase in pHH3 staining in S phase cells, indicative of premature mitosis (e.g.
HT-29, figure 3 ), but we also found that premature mitosis was not a requirement of sensitivity to WEE1 inhibition (e.g. LoVo, figure 3 ). Because a strong induction of DNA damage accompanied MK-1775-driven cytotoxicity, regardless of the effect on mitotic indices, our results suggest that DNA damage rather than premature mitotic entry is the dominant, though not exclusive, mechanism underlying effectiveness of WEE1 inhibition.
PKMYT1 and WEE1 both catalyze inhibitory phosphorylations on CDKs 1 and 2.
Our observations that low PKMYT1 mRNA expression is common among the most sensitive cell lines to MK-1775, and that knockdown of PKMYT1 can sensitize less responsive cell lines to MK-1775, together suggest functional redundancy between PKMYT1 and WEE1. In support of this, siRNA studies have shown that knockdown of PKMYT1 leads to similar, though less pronounced, abrogation of G2 cell cycle arrest and sensitization to DNA damaging agents (31;36;37). Furthermore, and similar to WEE1, overexpression of PKMYT1 is sufficient to induce a G2 cell cycle delay in HeLa cells (38) . Interestingly, this study found that the interaction of PKMYT1 with the CDK1-cyclin B1 complex, rather than PKMYT1 phosphorylation of CDK1-cyclin B1, was 
responsible for the cell cycle delay. This argues in favor of PKMYT1 expression rather than PKMYT1 activity as a potential indicator of MK-1775 sensitivity. In our evaluation of sensitivity and PKMYT1 mRNA expression among 305 cell lines, we found that many lines with relatively low levels of PKMYT1 did not respond to MK-1775 treatment (figure 6A). Despite the caveats inherent in comparing two independent data sets (internal response data and CCLE expression data), this suggests that PKMYT1 expression could be one of multiple prognostic factors when trying to predict the outcome of WEE1 inhibition.
MK-1775 has been widely studied in preclinical xenograft models as a chemotherapy or radiation sensitizer. These studies generally demonstrate that MK-1775 monotherapy is not an effective anticancer treatment. It should be noted, however, that MK-1775 is dosed below its monotherapy MTD of 60 mpk BID daily in these studies, arguably accounting for the differing single agent anticancer activity observed between previous studies and our work presented here. Importantly, in a study of patient-derived pancreatic carcinoma xenograft models, control groups receiving MK-1775 single agent treatment at doses considerably below MTD showed surprising tumor growth inhibition (39) . Unlike responses in the gemcitabine and MK-1775 combination arm, the anticancer activity of MK-1775 was not dependent on p53 mutational status (39), consistent with our own work (both A427 and LoVo xenograft models are wild type for TP53) and that determined by γH2AX staining in S-phase cells, is not only a hallmark of the response to WEE1 monotherapy (described here) but also of both the combination of the WEE1-and CHK1-inhibitors and CHK1 inhibitor monotherapy (42) . Our own work supports the in vivo combination benefit from combined WEE1 and CHK1 inhibition (data not shown and (43)). Notably, however, when MK-1775 and MK-8776 (formerly SCH-900776) are co-administered, the combination MTD requires both a dose reduction (60 mpk each drug alone to 40 mpk in combination) and a schedule reduction (BID daily dosing each drug alone to BID x2 weekly dosing in combination), reflecting increased toxicity of the combination (data not shown and (43) 
